Show simple item record

dc.contributor.authorHeydtmann, Mathis
dc.contributor.authorMacdonald, Benn
dc.contributor.authorLewsey, James
dc.contributor.authorMasson, Neil
dc.contributor.authorCunningham, Leona
dc.contributor.authorIrnazarow, Aleksandra
dc.contributor.authorNardone, Amanda
dc.contributor.authorCosgrave, Jan
dc.contributor.authorChick, Jonathan
dc.date.accessioned2018-06-29T21:36:41Z
dc.date.available2018-06-29T21:36:41Z
dc.date.issued2015-11
dc.identifierER3983
dc.identifier.citationHeydtmann, M., Macdonald, B., Lewsey, J., Masson, N., Cunningham, L., Irnazarow, A., Nardone, A., Cosgrave, J. & Chick, J. (2015) Tailored dose baclofen in patients with alcoholic liver disease: A case series with 2-year follow-up of hospitalisation, Addiction Research & Theory, vol. 23, , pp. 510-517,
dc.identifier.issn1606-6359
dc.identifier.urihttp://dx.doi.org/10.3109/16066359.2015.1040003
dc.identifier.urihttps://eresearch.qmu.ac.uk/handle/20.500.12289/3983
dc.description.abstractIntroduction: Alcohol addiction is a major health burden with its consequences including liver disease and frequent hospitalisations. We used tailored-dose baclofen in patients with alcoholic liver disease and investigated hospital re-admissions before and after baclofen dose was initiated as well as tolerability and patient-reported alcohol consumption. Methods: Fifty-three hospitalised patients with alcoholic liver disease started tailored dose baclofen (median: 5.05 months, median highest dose before tapering down: 60 mg). Patients were followed-up for hospitalisation data from the health board database (mean hospitalisation follow up: 31 months) and patients were sent standardized questionnaires. Results: Baclofen was generally well tolerated with dose reductions in four patients. In the 2 years after initiation of the treatment, patients spent on an average of 19.1 d in the hospital per year compared to 25.48 d before the treatment initiation (p = 0.59). Respondents (19 patients) reported a reduction in alcohol consumption by an average of 58.7% (240.1 g to 144.09 g). Conclusions: After initiation of the baclofen treatment, there was a trend towards decrease in hospitalisations and in patients who answered the questionnaire, alcohol consumption decreased. 2015 Informa UK Ltd. All rights reserved.
dc.format.extent510-517
dc.relation.ispartofAddiction Research & Theory
dc.titleTailored dose baclofen in patients with alcoholic liver disease: A case series with 2-year follow-up of hospitalisation
dc.typearticle
dcterms.accessRightsnone
dc.description.facultysch_nur
dc.description.volume23
dc.identifier.doihttp://doi:10.3109/16066359.2015.1040003
dc.description.ispublishedpub
dc.description.eprintid3983
rioxxterms.typearticle
qmu.authorChick, Jonathan
dc.description.statuspub
dc.description.number6


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record